BioSpace News Archive

The Janssen Pharmaceutical Companies of Johnson & Johnson announced positive topline results from its Phase 2b FRONTIER 1 clinical trial evaluating the novel, first and only oral interleukin-23 receptor antagonist peptide JNJ-2113 in adult patients with moderate-to-severe plaque psoriasis.1 The trial achieved all primary and secondary efficacy endpoints.

Galderma presented the latest data from its pivotal phase III OLYMPIA 2 trial at the 25th World Congress of Dermatology in Singapore.

Clarity Pharmaceuticals is pleased to announce it will be commencing a pivotal Phase III trial of its 64Cu SAR-bisPSMA diagnostic in prostate cancer following a successful end of phase meeting with the US Food and Drug Administration.

Jacobio Pharma announced its novel KRAS G12C inhibitor glecirasib’s pivotal study for pancreatic cancer has been approved from CDE, which became the first global pancreatic cancer registrational clinical study for KRAS G12C.

Dexcom, Inc. announced that Health Canada has approved the next-generation Dexcom G7 Continuous Glucose Monitoring System for people with all types of diabetes, ages two years and older.

OSE Immunotherapeutics SA announced that the United States Patent and Trademark Office has granted a new patent protecting Tedopi®, a therapeutic cancer vaccine treating HLA-A2 positive patients after secondary resistance to PD-1/PD-L1 immune checkpoint inhibitor treatment.

InnoCare Pharma announced the first psoriasis patient has been dosed in clinical trial of the Company’s TYK2 JH2 allosteric inhibitor ICP-488 in China.

Protagonist Therapeutics, Inc. announced positive topline results from the Phase 2b FRONTIER 1 clinical trial evaluating the oral interleukin-23 receptor antagonist JNJ-2113 in adult patients with moderate-to-severe plaque psoriasis presented at World Congress of Dermatology in Singapore.

Hansa Biopharma AB announces that, in accordance with chapter 4, 6§ of the Swedish Annual Accounts Act and RFR 2, it has elected to recognize a write-up of SEK 1.430 billion in intangible assets in the statutory financial statements of the parent company Hansa Biopharma AB.

PharmAla Biotech Holdings Inc. is pleased to announce that Cortexa, its Joint Venture with Australian company Vitura Health has executed its first purchase order for PharmAla’s GMP LaNeo MDMA, in both finished capsule and raw API forms.